Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884397 | 0.89 | AMY1A (0.48) | MEN1KMT2AMAPTLMNATSHR | |
| SCHEMBL4882983 | 0.87 | AMY1A (0.53) | L3MBTL1MEN1KMT2AMAPTLMNA | |
| SCHEMBL4877245 | 0.81 | ALDH1A1 (0.46) | MEN1KMT2AMAPTLMNATSHR | |
| SCHEMBL4884200 | 0.81 | MAPT (0.49) | L3MBTL1MEN1KMT2AMAPTLMNA | |
| SCHEMBL4881472 | 0.81 | MAPT (0.44) | MEN1KMT2AMAPTLMNATSHR | |
| SCHEMBL4883770 | 0.81 | KMT2A (0.51) | MEN1KMT2AMAPTLMNATSHR | |
| SCHEMBL4881251 | 0.80 | CA12 (0.46) | MEN1KMT2AMAPTLMNATSHR | |
| SCHEMBL4890060 | 0.79 | MAPT (0.58) | MEN1KMT2AMAPTLMNATSHR | |
| SCHEMBL4881640 | 0.79 | F10 (0.39) | MEN1KMT2AMAPTLMNATSHR | |
| SCHEMBL4881151 | 0.79 | MAPT (0.44) | MEN1KMT2AMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799649-B1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2014-06-25 | — | — | EP | claimed |
| US-20080090880-A1 | 3-(2-Hydroxyphenyl) Pyrazoles and Thier Use as Hsp90 Modulators | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-04-17 | — | — | US | claimed |
| EP-1799649-B1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-20080090880-A1 | 3-(2-Hydroxyphenyl) Pyrazoles and Thier Use as Hsp90 Modulators | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1799649-A1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | Merck Patent GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006039977-A1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090880-A1 | 3-(2-Hydroxyphenyl) Pyrazoles and Thier Use as Hsp90 Modulators | HSP90AB1, HSP90AA1, HSP90AB2P | L3MBTL1 2152/4885MEN1 4568/4885KMT2A 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.